• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Naphthofurans Naphthofurans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Naphthofurans

Recent Advances in Gelomulide A (122537-59-1) Research: A Comprehensive Review

Gelomulide A (CAS: 122537-59-1), a bioactive diterpenoid isolated from the marine-derived fungus Aspergillus sp., has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and promising pharmacological activities. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its therapeutic potential in various disease models. This research brief aims to provide an up-to-date overview of the latest findings related to Gelomulide A, highlighting its chemical properties, biological activities, and potential applications in drug development.

One of the most notable advancements in Gelomulide A research is the elucidation of its anti-cancer properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Gelomulide A exhibits potent cytotoxic effects against a panel of cancer cell lines, including breast, lung, and colon cancers. The compound was found to induce apoptosis through the activation of the intrinsic mitochondrial pathway, as evidenced by the upregulation of pro-apoptotic proteins such as Bax and caspase-3. Additionally, Gelomulide A showed selective toxicity towards cancer cells while sparing normal cells, suggesting a favorable therapeutic window.

In addition to its anti-cancer effects, recent research has explored the anti-inflammatory and immunomodulatory properties of Gelomulide A. A study published in Bioorganic & Medicinal Chemistry Letters in 2024 reported that Gelomulide A significantly inhibits the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in lipopolysaccharide (LPS)-stimulated macrophages. The compound was also found to suppress the activation of NF-κB, a key transcription factor involved in inflammatory responses. These findings suggest that Gelomulide A could serve as a lead compound for the development of novel anti-inflammatory agents.

Another area of active research is the synthetic modification of Gelomulide A to improve its pharmacokinetic properties and bioactivity. A recent paper in Organic Letters (2024) described the successful semi-synthesis of several Gelomulide A derivatives with enhanced solubility and stability. Among these derivatives, one compound exhibited a 2-fold increase in anti-proliferative activity against MCF-7 breast cancer cells compared to the parent compound. These modifications open new avenues for the development of Gelomulide A-based therapeutics with improved efficacy and reduced side effects.

Despite these promising findings, challenges remain in the clinical translation of Gelomulide A. Issues such as low natural abundance, complex synthesis, and limited in vivo data need to be addressed. However, ongoing research efforts, including the use of biotechnological approaches for large-scale production and the development of targeted delivery systems, are expected to overcome these hurdles. In conclusion, Gelomulide A represents a promising candidate for drug development, with potential applications in oncology, immunology, and beyond. Continued research into its mechanism of action and structural optimization will be crucial for realizing its full therapeutic potential.

• 38647-10-8(Tripdiolide)
• 38748-32-2(Triptolide)
• 139713-80-7(16-Hydroxytriptolide)
• 195883-06-8(Omtriptolide)
• 115753-79-2(2(3H)-Furanone,dihydro-3-[2-[(1R,2S,4aS,8aS)-octahydro-5,5,8a-trimethylspiro[naphthalene-2(1H),2'-oxiran]-1-yl]ethylidene]-,(3E)-)
• 17092-92-1(R-Dihydroactinidiolide)
• 122587-84-2([(1S)-2-[(1S,2R,4S,4aR,5R,8aR)-4-acetyloxy-4a-(acetyloxymethyl)-1,2-dimethylspiro[3,4,6,7,8,8a-hexahydro-2H-naphthalene-5,2'-oxirane]-1-yl]-1-(5-oxo-2H-furan-3-yl)ethyl] 2-methylbutanoate)
• 15356-74-8((±)-Dihydroactinidiolide)
• 73069-14-4(Atractylenolide II)
• 122587-83-1(Ajugamarin G1)